To specifically test if the extracellular VIM/IGF-1R interaction occurs in carcinomas, breast cancer cells or normal breast cells in culture were treated with recombinant VIM with or without IGF-1R inhibitors [119]. This evidence concerns the gene IGF1R and breast cancer.